CN117083080A - 抗体和紫杉烷联合疗法 - Google Patents

抗体和紫杉烷联合疗法 Download PDF

Info

Publication number
CN117083080A
CN117083080A CN202180092643.1A CN202180092643A CN117083080A CN 117083080 A CN117083080 A CN 117083080A CN 202180092643 A CN202180092643 A CN 202180092643A CN 117083080 A CN117083080 A CN 117083080A
Authority
CN
China
Prior art keywords
heavy chain
cancer
ser
val
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180092643.1A
Other languages
English (en)
Chinese (zh)
Inventor
U·沙辛
A·穆伊克
U·福斯曼
M·朱里-昆克尔
M·古普塔
T·艾哈迈迪
K·阿米里
G·巴贾杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiotech SA
Jian Mabao
Original Assignee
Debiotech SA
Jian Mabao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiotech SA, Jian Mabao filed Critical Debiotech SA
Publication of CN117083080A publication Critical patent/CN117083080A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202180092643.1A 2020-12-07 2021-12-07 抗体和紫杉烷联合疗法 Pending CN117083080A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122042P 2020-12-07 2020-12-07
US63/122,042 2020-12-07
PCT/EP2021/084659 WO2022122765A2 (en) 2020-12-07 2021-12-07 Antibody and taxane combination therapy

Publications (1)

Publication Number Publication Date
CN117083080A true CN117083080A (zh) 2023-11-17

Family

ID=79165020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180092643.1A Pending CN117083080A (zh) 2020-12-07 2021-12-07 抗体和紫杉烷联合疗法

Country Status (11)

Country Link
US (1) US20240109972A1 (https=)
EP (1) EP4255575A2 (https=)
JP (1) JP2023551980A (https=)
KR (1) KR20230128482A (https=)
CN (1) CN117083080A (https=)
AU (1) AU2021393908A1 (https=)
CA (1) CA3200895A1 (https=)
IL (1) IL303424A (https=)
MX (1) MX2023006404A (https=)
TW (1) TW202237081A (https=)
WO (1) WO2022122765A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
US20260034201A1 (en) * 2022-07-20 2026-02-05 Biontech Us Inc. Combination therapy with neoantigen vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR100745488B1 (ko) * 2006-07-04 2007-08-02 학교법인 울산공업학원 항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
JP2017507900A (ja) * 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
SI3242890T1 (sl) 2015-01-08 2020-01-31 BioNTech SE Agonistična sredstva, ki vežejo receptorje TNF
SG11202000198QA (en) * 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
TWI719765B (zh) * 2018-12-19 2021-02-21 美商建南德克公司 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療

Also Published As

Publication number Publication date
EP4255575A2 (en) 2023-10-11
AU2021393908A9 (en) 2024-04-18
AU2021393908A1 (en) 2023-06-22
US20240109972A1 (en) 2024-04-04
JP2023551980A (ja) 2023-12-13
IL303424A (en) 2023-08-01
WO2022122765A3 (en) 2022-08-11
MX2023006404A (es) 2023-09-15
KR20230128482A (ko) 2023-09-05
TW202237081A (zh) 2022-10-01
WO2022122765A2 (en) 2022-06-16
CA3200895A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
JP7809062B2 (ja) 療法において使用するための抗体
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
TW201731528A (zh) 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
TW201545759A (zh) 用於治療非小細胞肺癌之抗ｂ７－ｈ１及抗ｃｔｌａ－４抗體
US12570757B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
JP7459058B2 (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
CN106456764A (zh) 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
JP2022512851A (ja) がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン
CN114450028A (zh) Lag-3拮抗剂治疗的定量空间剖析
JP2022512866A (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
CN117083080A (zh) 抗体和紫杉烷联合疗法
JP2023554422A (ja) がんの治療のための多重特異性抗体
US20210324081A1 (en) Dosing
JP2026508608A (ja) メラノーマの治療における有効性の増強のためのｐｄ－１阻害剤及びｌａｇ－３阻害剤の組み合わせ
KR20250116794A (ko) 항-ctla4 항체를 펨브롤리주맙과 조합하여 사용하여 암을 치료하는 방법
CN119053340A (zh) 针对pd-l1和cd137的多特异性结合剂与抗pd-1抗体组合用于治疗癌症
HK40103860A (zh) 抗体和紫杉烷联合疗法
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
TW202515903A (zh) 手術前後基於抗ｐｄ－１之治療
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
HK40081753A (en) Antibodies for use in therapy
TW202508632A (zh) 使用抗ｐｄ－１及化學療法治療肺癌
HK40109234A (zh) 用於治疗癌症的方法和组合物
EA050156B1 (ru) Антитела для применения в терапии
CN118829446A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103860

Country of ref document: HK